Avantor, Inc. manufactures, distributes, and sells products and services to customers in the biopharma, healthcare, education and government, and advanced technologies and applied materials industries in the Americas, Europe, Asia, the Middle-East, and Africa.
Mediocre balance sheet with moderate growth potential.
Share Price & News
How has Avantor's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AVTR's share price has been volatile over the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: Insufficient data to determine how AVTR performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how AVTR performed against the US Market.
Price Volatility Vs. Market
How volatile is Avantor's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StEstimating The Fair Value Of Avantor, Inc. (NYSE:AVTR)
2 months ago | Simply Wall StWhat Kind Of Shareholders Own Avantor, Inc. (NYSE:AVTR)?
3 months ago | Simply Wall StCalculating The Intrinsic Value Of Avantor, Inc. (NYSE:AVTR)
Is Avantor undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AVTR ($12.96) is trading below our estimate of fair value ($14.11)
Significantly Below Fair Value: AVTR is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: AVTR is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.
PE vs Market: AVTR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVTR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVTR is overvalued based on its PB Ratio (5.1x) compared to the US Life Sciences industry average (4.6x).
How is Avantor forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVTR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: AVTR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AVTR's is expected to become profitable in the next 3 years.
Revenue vs Market: AVTR's revenue (3.2% per year) is forecast to grow slower than the US market (7% per year).
High Growth Revenue: AVTR's revenue (3.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AVTR's Return on Equity is forecast to be low in 3 years time (19.1%).
How has Avantor performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVTR is currently unprofitable.
Growing Profit Margin: AVTR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVTR is unprofitable, and losses have increased over the past 5 years at a rate of -35.2% per year.
Accelerating Growth: Unable to compare AVTR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVTR is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (21.5%).
Return on Equity
High ROE: AVTR has a negative Return on Equity (1.54%), as it is currently unprofitable.
How is Avantor's financial position?
Financial Position Analysis
Short Term Liabilities: AVTR's short term assets ($2.0B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: AVTR's short term assets ($2.0B) do not cover its long term liabilities ($6.2B).
Debt to Equity History and Analysis
Debt Level: AVTR's debt to equity ratio (205.4%) is considered high.
Reducing Debt: Insufficient data to determine if AVTR's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable AVTR has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: AVTR is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 37.1% per year.
What is Avantor's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AVTR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVTR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVTR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVTR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michael Stubblefield (47yo)
Mr. Michael Stubblefield has been the Chief Executive Officer of Avantor Performance Materials, Inc. since May 2014. Mr. Stubblefield he been President and Chief Executive Officer of Avantor, Inc. since 20 ...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD2.72M) is below average for companies of similar size in the US market ($USD7.52M).
Compensation vs Earnings: Insufficient data to compare Michael's compensation with company performance.
|Executive VP & CFO||1.33yrs||US$7.40m||0.47% $35.4m|
|Executive Vice President of Biopharma Production||1.75yrs||US$3.52m||0.19% $14.2m|
|Executive Vice President of Europe||1.5yrs||US$3.10m||0.19% $14.2m|
|Senior VP & Chief Accounting Officer||0.92yr||no data||no data|
|Executive VP & Chief Information Officer||2yrs||no data||no data|
|Vice President of Investor Relations||0.083yr||no data||no data|
|Chief Legal Officer||no data||no data||no data|
|Senior Director of Corporate Communications||no data||no data||no data|
|Executive VP & Chief Human Resources Officer||3.08yrs||no data||no data|
Experienced Management: AVTR's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
|Director||10.25yrs||no data||no data|
|Director||1yr||no data||no data|
|Director||2.42yrs||no data||no data|
|Independent Director||0.58yr||no data||no data|
|Director||5.25yrs||no data||no data|
|Director||1.42yrs||no data||no data|
Experienced Board: AVTR's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: AVTR only recently listed within the past 12 months, with total shares outstanding growing by 202.3% in the past year..
Avantor, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Avantor, Inc.
- Ticker: AVTR
- Exchange: NYSE
- Founded: 1904
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$7.499b
- Shares outstanding: 572.91m
- Website: https://www.avantorsciences.com
Number of Employees
- Avantor, Inc.
- Radnor Corporate Center
- Building One
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AVTR||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||May 2019|
|AVTR||XNYS (New York Stock Exchange, Inc. Floor)||Yes||Common Stock||US||USD||May 2019|
|AVG||BST (Boerse-Stuttgart)||Yes||Common Stock||DE||EUR||May 2019|
|AVTR.PRA||NYSE (New York Stock Exchange)||6.25 PFD CNV SR||US||USD||May 2019|
|AVG||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2019|
|AVTR||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||May 2019|
Avantor, Inc. manufactures, distributes, and sells products and services to customers in the biopharma, healthcare, education and government, and advanced technologies and applied materials industries in the Americas, Europe, Asia, the Middle-East, and Africa. The company’s materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, and process chromatography resins and columns, as well as analytical sample prep, education, and microbiology and clinical trial kits. Its equipment and instrumentation products comprise filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and environment supplies. The company also provides onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/09 03:36|
|End of Day Share Price||2020/04/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.